COSCIENS Biopharma Inc lost $3.27 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters COSCIENS Biopharma Inc has filed alongside them.
FY2025 annual
EPS (Diluted)-$3.27
YoYn/m
Source SEC Filings (20-F/6-K)Latest period FY2025, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
CSCIF EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
COSCIENS Biopharma Inc lost $3.27 per diluted share in fiscal year 2025.
COSCIENS Biopharma Inc (CSCIF) reported a loss of $5.93 per diluted share in fiscal year 2024 and a loss of $3.27 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
COSCIENS Biopharma Inc (CSCIF) reported -$0.68 in diluted earnings per share in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what COSCIENS Biopharma Inc (CSCIF) reported on that line in every period on record.
